Katherine A Janeway

List of Publications by Citations

117 papers	5,385 citations	36 h-index	72 g-index
127 ext. papers	6,747 ext. citations	7.2 avg, IF	5.42 L-index

#	Paper	IF	Citations
117	Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 314-8	11.5	482
116	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E5564-73	11.5	275
115	Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. *Lancet Oncology, The*, **2016**, 17, 1396-1408	21.7	253
114	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. *Clinical Cancer Research*, **2017**, 23, e38-e45	12.9	245
113	Institutional implementation of clinical tumor profiling on an unselected cancer population. *JCI Insight*, **2016**, 1, e87062	9.9	245
112	Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. *Cancer Discovery*, **2013**, 3, 648-57	24.4	228
111	Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. *JAMA Oncology*, **2016**, 2, 922-8	13.4	187
110	Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. *European Journal of Cancer*, **2019**, 109, 36-50	7.5	180
109	Future directions in the treatment of osteosarcoma. *Current Opinion in Pediatrics*, **2016**, 28, 26-33	3.2	179
108	Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. *Lancet Oncology, The*, **2010**, 11, 670-8	21.7	152
107	Differentiation of NUT midline carcinoma by epigenomic reprogramming. *Cancer Research*, **2011**, 71, 2686-96	10.1	140
106	Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. *Cancer Research*, **2007**, 67, 9084-8	10.1	136
105	Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. *JAMA Oncology*, **2016**, 2, 608-615	13.4	128
104	Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. *Clinical Cancer Research*, **2017**, 23, e68-e75	12.9	127
103	Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children℞ Oncology Group. *Cancer*, **2012**, 118, 4597-605	6.4	126
102	Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. *Pediatric Blood and Cancer*, **2009**, 52, 767-71	3	124
101	Children℞ Oncology Group℞ 2013 blueprint for research: bone tumors. *Pediatric Blood and Cancer*, **2013**, 60, 1009-15	3	118

100	Toward a drug development path that targets metastatic progression in osteosarcoma. *Clinical Cancer Research*, **2014**, 20, 4200-9	12.9	103
99	Pediatric gastrointestinal stromal tumors. *Hematology/Oncology Clinics of North America*, **2009**, 23, 15-34, vii	3.1	101
98	Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. *Journal of Clinical Oncology*, **2016**, 34, 3031-8	2.2	92
97	Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. *Modern Pathology*, **2018**, 31, 463-473	9.8	86
96	MicroRNA paraffin-based studies in osteosarcoma reveal reproducible independent prognostic profiles at 14q32. *Genome Medicine*, **2013**, 5, 2	14.4	69
95	Precision medicine in pediatric oncology. *Current Opinion in Pediatrics*, **2018**, 30, 17-24	3.2	62
94	Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. *Cancer Research*, **2017**, 77, 509-519	10.1	60
93	Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	60
92	Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. *International Journal of Cancer*, **2010**, 127, 2718-22	7.5	57
91	Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. *Cancer*, **2019**, 125, 3514-3525	6.4	51
90	Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. *British Journal of Cancer*, **2018**, 119, 615-621	8.7	47
89	High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. *Journal of Clinical Oncology*, **2019**, 37, 3192-3202	2.2	45
88	Carpal tunnel syndrome and workers' compensation among an occupational clinic population in New York State. *American Journal of Industrial Medicine*, **1999**, 35, 335-42	2.7	41
87	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. *Neuro-Oncology*, **2017**, 19, 986-996	1	39
86	Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. *Journal of Clinical Oncology*, **2017**, 35, 523-528	2.2	39
85	Special considerations in pediatric gastrointestinal tumors. *Journal of Surgical Oncology*, **2011**, 104, 928-32	2.8	39
84	A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. *Clinical Cancer Research*, **2019**, 25, 1343-1357	12.9	39
83	Pediatric gastrointestinal stromal tumor. *Seminars in Pediatric Surgery*, **2012**, 21, 31-43	2.1	37

82	Future of clinical genomics in pediatric oncology. *Journal of Clinical Oncology*, **2013**, 31, 1893-903	2.2	36
81	Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. *JCO Precision Oncology*, **2018**, 2018,	3.6	36
80	Pediatric oncology enters an era of precision medicine. *Current Problems in Cancer*, **2017**, 41, 194-200	2.3	32
79	Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. *Pediatric Blood and Cancer*, **2016**, 63, 1974-82	3	32
78	Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. *Journal of Physical Education and Sports Management*, **2015**, 1, a000471	2.8	32
77	Treatment guidelines for gastrointestinal stromal tumors in children and young adults. *Journal of Pediatric Hematology/Oncology*, **2012**, 34 Suppl 2, S69-72	1.2	32
76	Integrated genetic and pharmacologic interrogation of rare cancers. *Nature Communications*, **2016**, 7, 11987	17.4	32
75	Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. *F1000Research*, **2019**, 8,	3.6	31
74	Post-transcriptional dysregulation by miRNAs is implicated in the pathogenesis of gastrointestinal stromal tumor [GIST]. *PLoS ONE*, **2013**, 8, e64102	3.7	31
73	Modeling human osteosarcoma in the mouse: From bedside to bench. *Bone*, **2010**, 47, 859-65	4.7	29
72	Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. *Cancer Genetics*, **2016**, 209, 182-94	2.3	29
71	Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. *Pediatric Blood and Cancer*, **2018**, 65, e26896	3	28
70	Canine osteosarcoma genome sequencing identifies recurrent mutations in and the histone methyltransferase gene. *Communications Biology*, **2019**, 2, 266	6.7	28
69	Ushering in the next generation of precision trials for pediatric cancer. *Science*, **2019**, 363, 1175-1181	33.3	27
68	An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. *Journal of Hematology and Oncology*, **2017**, 10, 107	22.4	26
67	Recurrent RET gene fusions in paediatric spindle mesenchymal neoplasms. *Histopathology*, **2020**, 76, 1032-1041	7.3	24
66	Clinical trial enrollment of adolescents and young adults with sarcoma. *Cancer*, **2017**, 123, 3434-3440	6.4	22
65	Assessing the Prognostic Significance of Histologic Response in Osteosarcoma: A Comparison of Outcomes on CCG-782 and INT0133-A Report From the Children's Oncology Group Bone Tumor Committee. *Pediatric Blood and Cancer*, **2016**, 63, 1737-43	3	22

64	Advances in the Treatment of Pediatric Bone Sarcomas. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 725-735	7.1	20
63	Renal medullary carcinomas depend upon loss and are sensitive to proteasome inhibition. *ELife*, **2019**, 8,	8.9	20
62	Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group. *European Journal of Cancer*, **2019**, 121, 177-183	7.5	19
61	Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. *Clinical Cancer Research*, **2020**, 26, 1837-1845	12.9	19
60	Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. *Clinical Cancer Research*, **2016**, 22, 3643-50	12.9	18
59	Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2019**, 66, e27444	3	18
58	A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation. *Pediatric Blood and Cancer*, **2015**, 62, 450-5	3	17
57	HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. *Pediatric Blood and Cancer*, **2014**, 61, 1558-64	3	16
56	Emerging concepts for PI3K/mTOR inhibition as a potential treatment for osteosarcoma. *F1000Research*, **2016**, 5,	3.6	16
55	Advances in the Treatment of Pediatric Bone Sarcomas. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2017**, 37, 725-735	7.1	16
54	DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. *Modern Pathology*, **2020**, 33, 1910-1921	9.8	16
53	Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. *Pediatric Blood and Cancer*, **2012**, 58, 181-4	3	15
52	Pediatric and wild-type gastrointestinal stromal tumor: new therapeutic approaches. *Current Opinion in Oncology*, **2010**, 22, 347-50	4.2	13
51	Marketing of personalized cancer care on the web: an analysis of Internet websites. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	12
50	Pediatric Oncology Provider Views on Performing a Biopsy of Solid Tumors in Children with Relapsed or Refractory Disease for the Purpose of Genomic Profiling. *Annals of Surgical Oncology*, **2016**, 23, 990-997	3.1	12
49	A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2019**, 66, e27524	3	12
48	OncoTree: A Cancer Classification System for Precision Oncology. *JCO Clinical Cancer Informatics*, **2021**, 5, 221-230	5.2	11
47	Liposomal doxorubicin: Effective treatment for pediatric desmoid fibromatosis. *Pediatric Blood and Cancer*, **2017**, 64, e26375	3	10

46	A Novel Fusion in Pediatric Medullary Thyroid Carcinoma. *Thyroid*, **2019**, 29, 1704-1707	6.2	10
45	Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. *Journal of the National Cancer Institute*, **2020**, 112, 224-228	9.7	10
44	Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. *Clinical Cancer Research*, **2020**, 26, 2882-2890	12.9	10
43	Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. *Sarcoma*, **2018**, 2018, 1712964	3.1	10
42	Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children℞ Oncology Group. *Pediatric Blood and Cancer*, **2016**, 63, 370-1	3	9
41	Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. *Cancer Chemotherapy and Pharmacology*, **2019**, 84, 41-50	3.5	8
40	New strategies in sarcoma therapy: linking biology and novel agents. *Clinical Cancer Research*, **2012**, 18, 5837-44	12.9	8
39	Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children℞ Oncology Group Report. *Journal of Clinical Oncology*, **2021**, JCO2100358	2.2	8
38	Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children℞ Oncology Group. *Journal of Surgical Oncology*, **2016**, 113, 351-4	2.8	8
37	The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. *Oncologist*, **2020**, 25, e39-e47	5.7	8
36	Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors. *JCO Precision Oncology*, **2019**, 3,	3.6	7
35	Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children℞ Oncology Group and the QuadW Foundation. *PLoS ONE*, **2017**, 12, e0181204	3.7	6
34	Cardiac paraganglioma in an adolescent. *Circulation*, **2012**, 125, e322-4	16.7	6
33	The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. *Pediatric Blood and Cancer*, **2020**, 67, e28559	3	6
32	Safety and efficacy of gamma-secretase inhibitor nirogacestat (PF-03084014) in desmoid tumor: Report of four pediatric/young adult cases. *Pediatric Blood and Cancer*, **2020**, 67, e28636	3	6
31	The case for informative phase 2 trials in osteosarcoma. *Lancet Oncology, The*, **2016**, 17, 1022-1023	21.7	5
30	PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate?. *Journal of Pediatric Hematology/Oncology*, **2020**, 42, 482-487	1.2	5
29	Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children℞ Oncology Group. *Sarcoma*, **2020**, 2020, 3498549	3.1	5

28	Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome. *New England Journal of Medicine*, **2021**, 385, 2059-2065	59.2	4
27	Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. *JCO Clinical Cancer Informatics*, **2021**, 5, 1034-1043	5.2	4
26	Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing.. *JCO Precision Oncology*, **2020**, 4, 1084-1097	3.6	4
25	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. *Cancer Discovery*, **2021**, 11, 1424-1439	24.4	4
24	Dose Intensification Improves the Outcome of Ewing Sarcoma. *Journal of Clinical Oncology*, **2018**, JCO2018793489	2.2	3
23	Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.. *Journal of Clinical Oncology*, **2022**, JCO2102838	2.2	3
22	Molecular profiling in the clinic: Moving from feasibility assessment to evaluating clinical impact. *Pediatric Blood and Cancer*, **2017**, 64, e26482	3	2
21	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. *Blood*, **2018**, 132, 261-261	2.2	2
20	Retrospective evaluation of single patient investigational new drug (IND) requests in pediatric oncology. *Cancer Medicine*, **2021**, 10, 2310	4.8	2
19	Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. *Pediatric Blood and Cancer*, **2021**, 68, e29188	3	2
18	A Distinctive Genomic and Immunohistochemical Profile for NOTCH3 and PDGFRB in Myofibroma With Diagnostic and Therapeutic Implications. *International Journal of Surgical Pathology*, **2020**, 28, 128-137	1.2	2
17	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. *JAMA Network Open*, **2021**, 4, e2117547	10.4	2
16	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.. *Journal of Clinical Oncology*, **2022**, JCO2102840	2.2	2
15	Phase I/II Study of Stereotactic Body Radiation Therapy for Pulmonary Metastases in Pediatric Patients. *Advances in Radiation Oncology*, **2020**, 5, 1267-1273	3.3	1
14	Making the most of small samples: Optimization of tissue allocation of pediatric solid tumors for clinical and research use. *Pediatric Blood and Cancer*, **2020**, 67, e28326	3	1
13	Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival. *Cancer Research*, **2021**, 81, 3971-3984	10.1	1
12	Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. *Pediatric Blood and Cancer*, **2021**, 68, e28834	3	1
11	Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. *Cancer Chemotherapy and Pharmacology*, **2021**, 87, 621-634	3.5	1

10	Assessment of BCOR Internal Tandem Duplications in Pediatric Cancers by Targeted RNA Sequencing. *Journal of Molecular Diagnostics*, **2021**, 23, 1269-1278	5.1	1
9	Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. *Journal of Adolescent and Young Adult Oncology*, **2021**,	2.2	1
8	Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 1564-1568	5	0
7	Desmoid tumors of the head and neck in the pediatric population: Has anything changed?. *International Journal of Pediatric Otorhinolaryngology*, **2021**, 140, 110511	1.7	0
6	Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group. *Pediatric Blood and Cancer*, **2021**, 68, e29333	3	0
5	Ga-DOTATATE PET and functional imaging in pediatric pheochromocytoma and paraganglioma.. *Pediatric Blood and Cancer*, **2022**, e29740	3	0
4	Diagnostic Utility of Targeted Next Generation Sequencing in Patients with Vascular Anomalies. *Blood*, **2020**, 136, 8-9	2.2	
3	Inherited GIST **2017**, 45-57		
2	A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine. *Pediatric Blood and Cancer*, **2021**, 68, e28780	3	
1	Reply to J.-G. Wang et al.. *Journal of Clinical Oncology*, **2022**, JCO2102922	2.2	